The maximum indicated daily maintenance dose for SOMAVERT is 30 mg.
Study Description: Data from a randomized, double-blind, placebo-controlled, fixed daily pegvisomant dose (10 mg, 15 mg, and 20 mg), 12-week study in 112 subjects with acromegaly who may have been previously treated with surgery, radiation therapy, and/or drug therapy. Total score for signs and symptoms are based on scores for 5 symptoms, each graded in severity from 0 (absent) to 8 (worst). Thus, the total possible score ranged from 0 to 40. The 5 symptoms graded were fatigue, excessive perspiration, headache, arthralgia, and soft-tissue swelling. The mean change from baseline for each dose was calculated averaging the change in total score at 12 weeks across all patients in that dosing arm. Mean baseline total score for signs and symptoms in all dose groups combined was 15.2.